$20.28 B
Share price
Change (1 day)
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Earnings for BeiGene (BGNE)

Earnings in 2023 (TTM): -$1.3 B

According to BeiGene 's latest financial reports the company's current earnings (TTM) are -$1.3 B. In 2022 the company made an earning of -$1.79 B a decrease over its 2021 earnings that were of -$1.44 B.The earnings displayed on this page is the company's Pretax Income.

Earnings history for BeiGene from 2015 to 2023

Annual earnings

Year Earnings Change
2023 (TTM)-$1.3 B-27.78%
2022-$1.79 B24.39%
2021-$1.44 B-13.21%
2020-$1.66 B72.69%
2019-$0.96 B36.01%
2018-$0.71 B616.83%
2017-$98.46 M-16.53%
2016-$0.12 B112.96%
2015-$55.39 M

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-$0.22 B-83.44%๐Ÿ‡บ๐Ÿ‡ธ USA
-$20.19 M-98.44%๐Ÿ‡บ๐Ÿ‡ธ USA